HLA-A2 antibody [BB7.2]
GTX75803
ApplicationsFlow Cytometry, ImmunoPrecipitation, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen
Product group Antibodies
TargetHLA-A
Overview
- SupplierGeneTex
- Product NameHLA-A2 antibody [BB7.2]
- Delivery Days Customer9
- Application Supplier NoteFACS: 10microg/ml. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsFlow Cytometry, ImmunoPrecipitation, ImmunoHistoChemistry, ImmunoHistoChemistry Frozen
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDBB7.2
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID3105
- Target nameHLA-A
- Target descriptionmajor histocompatibility complex, class I, A
- Target synonymsHLAA, HLA class I histocompatibility antigen, A alpha chain, HLA class I histocompatibility antigen, A-1 alpha chain, MHC class I antigen HLA-A heavy chain, leukocyte antigen class I-A
- HostMouse
- IsotypeIgG2b
- Scientific DescriptionHLA-A belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domains, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region, and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. Hundreds of HLA-A alleles have been described. [provided by RefSeq, Jul 2008]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Repáraz D, Ruiz M, Llopiz D, et al. Neoantigens as potential vaccines in hepatocellular carcinoma. J Immunother Cancer. 2022,10(2). doi: 10.1136/jitc-2021-003978Read this paper
- Bonaventura P, Alcazer V, Mutez V, et al. Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Sci Adv. 2022,8(4):eabj3671. doi: 10.1126/sciadv.abj3671Read this paper
- Wu L, Zhang H, Jiang Y, et al. Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells. Proc Natl Acad Sci U S A. 2018,115(19):E4453-E4462. doi: 10.1073/pnas.1800550115Read this paper
- Chung B, Stuge TB, Murad JP, et al. Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Cell Rep. 2014,8(3):871-882. doi: 10.1016/j.celrep.2014.06.052Read this paper
- Liu B, Zhong S, Malecek K, et al. 2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system. Eur J Immunol. 2014,44(1):239-50. doi: 10.1002/eji.201343774Read this paper



